Anti-Tumor Nucleic Acid Drug Discovery Platform
Successful application of nucleic acid therapeutics faces many challenges, including delivery efficiency and off-target effects. To address these challenges, WuXi...
Continue Reading
Successful application of nucleic acid therapeutics faces many challenges, including delivery efficiency and off-target effects. To address these challenges, WuXi...
Continue Reading
Antibody‒drug conjugates (ADCs), which combine the advantages of monoclonal antibodies with precise targeting and payloads, show great potential as cancer...
Continue Reading
Screen your compounds across our comprehensive cell screening panel of over 600 authenticated, validated human cancer cell lines covering 50...
Continue Reading
Atopic dermatitis (AD) is the most common, chronic inflammatory skin disease. To support drug discovery research in this area, WuXi...
Continue Reading
Cell migration, invasion, and adhesion are pivotal steps in cancer metastasis. To support research in this field, WuXi AppTec offers...
Continue Reading
WuXi AppTec offers Jurkat reporter cell lines for immunotherapy drug screening. Our platform includes CD8+, TCR knockout and CD16-expressing Jurkat-NFAT-Luc...
Continue Reading
Our in vivo alopecia platform is comprised of both non-cicatricial and cicatricial alopecia models, including skin graft-induced alopecia areata (AA)...
Continue Reading
Oncolytic viruses (OVs) are emerging as a promising therapeutic approach for treating cancer. OVs are capable of both tumor-specific cell...
Continue Reading
Leverage our panel of in vitro immunology assays to accelerate your lead optimization efforts. WuXi AppTec offers a comprehensive platform of...
Continue Reading